Assessing clinical and metabolic responses related to hyperlipidemia, MASLD and type 2 diabetes: sleeve versus RYGB
Nutrition · 2024
DOI: 10.1016/j.nut.2024.112530 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Nutrition, 2024. Verfasst von Sharvika Bharatselvam und 6 weiteren Autor:innen. Beteiligte Einrichtung: Toronto General Hospital, University Health Network, Toronto, Canada. Hauptthemen laut MEDLINE: Obesity, Morbid, Gastric Bypass, Gastrectomy, Hyperlipidemias. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 71 Literaturangaben. Gefördert von: Canadian Institutes of Health Research.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE: Both Roux-en-Y gastric bypass (RYGB) and laparoscopic sleeve gastrectomy (LSG) are effective at inducing weight loss, but more information is needed on their comparative effectiveness at improving clinical/biochemical outcomes related to the presence of hyperlipidemia, metabolic dysfunction-associated steatotic liver disease (MASLD), or type 2 diabetes (T2D) at baseline. Here we aimed to assess this in real-world practice. METHODS: This is a prospective cross-sectional and cohort study of 142 patients who underwent RYGB or LSG as per clinical practice. Clinical/biochemical data were collected at baseline, prior to surgery and 12 months post-bariatric surgery. Liver biopsy was performed during surgery to diagnose MASLD. The main outcome was 12-month changes in lipid parameters, mainly total cholesterol, between types of surgery. RESULTS: A TOTAL OF: 107 participants underwent RYGB and 35 underwent LSG. Both groups were similar at baseline except for a higher proportion of males and waist circumference in the LSG group. At 12 months postsurgery, RYGB versus LSG resulted in a significantly lower body mass index, triglycerides, total cholesterol, and low-density lipoprotein. However, alanine aminotransferase was significantly lower in those who underwent LSG. In subgroup analyses RYGB was superior at improving lipid-related parameters in those with hyperlipidemia, whereas LSG was superior at reducing alanine aminotransferase in those with MASLD. CONCLUSIONS: RYGB versus LSG leads to greater reductions in body mass index and lipid parameters, especially in those with hyperlipidemia, whereas LSG showed greater improvements in liver enzymes in those with MASLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Toronto General Hospital, University Health Network, Toronto, Canada.
- Toronto General Hospital, University Health Network, Toronto, Canada; Institute of Medical Science, University of Toronto, Toronto, Canada.
- Toronto General Hospital, University Health Network, Toronto, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
- Division of Surgery, University of Toronto, Toronto, Canada; Division of General Surgery, Toronto Western Hospital, University Health Network, Toronto, Canada.
- Toronto General Hospital, University Health Network, Toronto, Canada; Institute of Medical Science, University of Toronto, Toronto, Canada; Department of Medicine, University of Toronto, Toronto, Canada; Department of N…
Förderung
- Canadian Institutes of Health Research
Zitieren
APA
Bharatselvam, S., Schwenger, K. J. P., Ghorbani, Y., Fischer, S. E., Jackson, T. D., Okrainec, A., & Allard, J. P. (2024). Assessing clinical and metabolic responses related to hyperlipidemia, MASLD and type 2 diabetes: sleeve versus RYGB. Nutrition. https://doi.org/10.1016/j.nut.2024.112530
Vancouver
Bharatselvam S, Schwenger KJP, Ghorbani Y, Fischer SE, Jackson TD, Okrainec A, et al. Assessing clinical and metabolic responses related to hyperlipidemia, MASLD and type 2 diabetes: sleeve versus RYGB. Nutrition. 2024. doi:10.1016/j.nut.2024.112530
BibTeX
@article{Bharatselvam2024,
author = {Bharatselvam, Sharvika and Schwenger, Katherine J P and Ghorbani, Yasaman and Fischer, Sandra E and Jackson, Timothy D and Okrainec, Allan and Allard, Johane P},
title = {Assessing clinical and metabolic responses related to hyperlipidemia, MASLD and type 2 diabetes: sleeve versus RYGB},
journal = {Nutrition},
year = {2024},
doi = {10.1016/j.nut.2024.112530}
}
EUVIMED